Somatostatin receptors have been described not only on neuroendocrine tumor cells but in many normal cells and are particularly upregulated in lymphocytes during their activation in inflammatory conditions. Thus, the use of scintigraphy with radiolabelled somatostatin analogues (SRS) may have an impact in the diagnosis of some inflammatory disease, as well in defining the state of activity of the disease, in therapy decision making, and in evaluating the efficacy of anti-inflammatory drugs. We review here the use of SSR(s) in inflammatory conditions according to what has been published so far in the literature and according to our experience in this field.